Form 4: Arcturus Therapeutics Director Edward Holmes Receives Annual Stock Option Grant

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual board compensation.

Summary

• Edward W. Holmes, a Director of Arcturus Therapeutics Holdings Inc. (ARCT), was granted 15,000 stock options on June 9, 2025.
• These options have an exercise price of $12.54 per share.
• The options will vest monthly over a one-year period from the grant date.
• The expiration date for these options is June 9, 2035.
• This grant represents the 2025 annual compensation for Mr. Holmes as a member of the Issuer's Board of Directors.
• Following this transaction, Mr. Holmes beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine annual equity grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. There are no unexpected positive or negative disclosures.

Positives

• The grant of stock options aligns the interests of Director Edward W. Holmes with those of shareholders, as the value of the options increases with the company's stock price.
• This represents a routine annual compensation grant, indicating stability in the company's governance and compensation practices for its board members.

Negatives

• No negative information is disclosed in this Form 4 filing.

Risks

• This Form 4 filing, which reports an insider transaction, does not contain information regarding company-specific or industry-wide risks.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• Shares underlying the option vest monthly over a one year period from the date of grant.
• This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Industry Context

The granting of stock options to board members is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation that aligns the interests of directors with shareholder value creation. This practice is particularly prevalent in growth-oriented sectors where stock performance is a key indicator of success.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector like Arcturus Therapeutics.
• While specific grant sizes and exercise prices vary based on company size, performance, and individual roles, the use of equity-based compensation like stock options is a global benchmark for aligning executive and board incentives with shareholder returns.
• Comparable companies in the biotech space often utilize similar equity grants for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of 15,000 stock options to Edward W. Holmes, a Director of Arcturus Therapeutics, constitutes a related party transaction as it involves compensation provided by the company to a member of its Board of Directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The granted stock options will vest monthly over a one-year period from June 9, 2025.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, SEC filing, Form 4, insider transaction, stock options, director compensation, equity grant, beneficial ownership, Edward W. Holmes, biotechnology, pharmaceutical